The preclinical company is located in Japan with investment from leading Japanese institutional investors, including The University of Tokyo Edge Capital Partners.

RegCell has developed a best-in-class proprietary platform that allows the generation of epigenetically reprogrammed antigen-specific Tregs that are stable in vivo and maintain a high degree of functionality to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation.